Oncology | Preclinical Developments | FRANCE

AB Science SA

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

AB Science to Present Results from AB8939 Preclinical Program in Acute Myeloid Leukemia at EHA 2020 Annual Congress

Lead Product(s): AB8939

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 10, 2020

Details:

The therapeutic potential of AB8939 in AML is demonstrated using Ara-C resistant and azacitidine resistant patient-derived xenograft (PDX) models.

OSE Immunotherapeutics SA

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

OSE Immunotherapeutics Presents New Data Supporting Bispecific Antibody Checkpoint Inhibitor Platform and Bifunctional Therapy Targeting PD-...

Lead Product(s): BiCKI-IL-7

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 10, 2020

Details:

The AACR update presentations show that BiCKI®-IL-7 will help overcome resistance mechanisms to anti-PD(L)-1 therapies and could potentially address the needs of a patient population in immune escape from checkpoint inhibitor treatment.

OSE Immunotherapeutics SA

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

OSE Immunotherapeutics Identifies Monoclonal Antibody Antagonists of CLEC-1 as New Checkpoint Inhibitors of Immune Myeloid Cells

Lead Product(s): Anti-CLEC-1 monoclonal antibody

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 09, 2020

Details:

OSE Immunotherapeutics’ poster presentation featured CLEC-1 antagonist monoclonal antibodies, which have been identified as an innovative immunotherapy that releases the brakes on macrophage phagocytosis and dendritic cells and demonstrates synergistic anti-cancer effects.

Transgene

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Transgene and BioInvent Present Preclinical Data Demonstrating BT-001’s Powerful Activity Against Solid Tumors

Lead Product(s): BT-001

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 15, 2020

Details:

AACR abstract outlines the broad therapeutic potential of BT-001, an oncolytic virus encoding an anti-CTLA4 antibody.

Stimunity

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Portage Makes Additional Investment in Stimunity S.A.S

Lead Product(s): STI-001

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Portage Biotech

Deal Size: $0.9 million Upfront Cash: Undisclosed

Deal Type: Financing May 11, 2020

Details:

Stimunity has reached a major milestone in its preclinical development plan and the additional financing will enable it to start the manufacturing of its biologic cGAMP-VLP (STI-001) lead compound.

Transgene

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Transgene and BioInvent to Present Data on BT-001, an Oncolytic Virus Encoding for an Anti-CTLA4 Antibody, at Upcoming Congresses

Lead Product(s): BT-001

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 03, 2020

Details:

Comprehensive data package supports pending clinical trial application for the first-in-human study of BT-001.

Onxeo

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Onxeo to Present Next-Generation PARP inhibitor, OX401, at the European ESMO-TAT Congress 2020

Lead Product(s): OX401

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 27, 2020

Details:

The data will showcase the high affinity with PARP that leads to DDR inhibition, metabolic exhaustion and activation of the innate immune response, specifically in tumoral cells.

Advanced BioDesign

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Advanced BioDesign Raises Additional €9 Million From Xerys Funds

Lead Product(s): ABD-3001

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Xerys Funds

Deal Size: $9.8 million Upfront Cash: Undisclosed

Deal Type: Funding February 26, 2020

Details:

Advanced BioDesign will finalise its preclinical studies and submit a clinical trial authorization to start clinical phase I in AML in early 2021.

Onxeo

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Onxeo to Present Next-Generation PARP Inhibitor, OX401, at PARP & DDR Inhibitors Summit 2020

Lead Product(s): OX401

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 28, 2020

Details:

Onxeo is building a strong preclinical data set for OX401, optimized for both PARP inhibition and STING response as well as bypass resistance., as homologous recombination deficiency requirements.

Seekyo

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

BIOTECH START-UP SEEKYO RAISES €800K WITH LEVERAGE FROM FRENCH TECH SEED FUND

Lead Product(s): SKY01

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: French Tech Seed

Deal Size: $0.8 million Upfront Cash: Undisclosed

Deal Type: Funding January 20, 2020

Details:

These funds will allow the company to accelerate the development of its flagship drug candidate, before launching a new fundraising round that will address clinical trials.

Find

Find Novel Oncology Drugs in Preclinical Development in FRANCE

France

Product Type

Companies

AB Science SA

AB Science to Present Results from AB8939 Preclinical Program in Acute Myeloid Leukemia at EHA 2020 Annual Congress

OSE Immunotherapeutics SA

OSE Immunotherapeutics Presents New Data Supporting Bispecific Antibody Checkpoint Inhibitor Platform and Bifunctional Therapy Targeting PD-...

OSE Immunotherapeutics SA

OSE Immunotherapeutics Identifies Monoclonal Antibody Antagonists of CLEC-1 as New Checkpoint Inhibitors of Immune Myeloid Cells

Transgene

Transgene and BioInvent Present Preclinical Data Demonstrating BT-001’s Powerful Activity Against Solid Tumors

Stimunity

Portage Makes Additional Investment in Stimunity S.A.S

Transgene

Transgene and BioInvent to Present Data on BT-001, an Oncolytic Virus Encoding for an Anti-CTLA4 Antibody, at Upcoming Congresses

Onxeo

Onxeo to Present Next-Generation PARP inhibitor, OX401, at the European ESMO-TAT Congress 2020

Advanced BioDesign

Advanced BioDesign Raises Additional €9 Million From Xerys Funds

Onxeo

Onxeo to Present Next-Generation PARP Inhibitor, OX401, at PARP & DDR Inhibitors Summit 2020

Seekyo

BIOTECH START-UP SEEKYO RAISES €800K WITH LEVERAGE FROM FRENCH TECH SEED FUND